Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study

Sarah A. Taylor; Dorothy J. Giroux; Kurt A. Jaeckle; Timothy J. Panella; Shaker R. Dakhil; S. Clifford Schold

doi:10.1023/A:1006273214056

Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study

Sarah A. Taylor, Dorothy J. Giroux, Kurt A. Jaeckle, Timothy J. Panella, Shaker R. Dakhil, S. Clifford Schold

Neurology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Didemnin B 6.3 mg/m² was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.

Original language	English (US)
Pages (from-to)	331-332
Number of pages	2
Journal	Investigational New Drugs
Volume	16
Issue number	4
DOIs	https://doi.org/10.1023/A:1006273214056
State	Published - 1998

Keywords

Central nervous system tumors
Didemnin B

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1023/A:1006273214056

Cite this

@article{cf83ce38aa6b48a8834af620ad9ebc0f,

title = "Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study",

abstract = "Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.",

keywords = "Central nervous system tumors, Didemnin B",

author = "Taylor, {Sarah A.} and Giroux, {Dorothy J.} and Jaeckle, {Kurt A.} and Panella, {Timothy J.} and Dakhil, {Shaker R.} and Schold, {S. Clifford}",

note = "Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA38926, CA32102, CA12644, CA58861, CA22433, CA46136, CA04920, CA58686, CA20319, CA46282, CA35431, CD35176, CA45560 and CA52654.",

year = "1998",

doi = "10.1023/A:1006273214056",

language = "English (US)",

volume = "16",

pages = "331--332",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - Phase II study of Didemnin B in central nervous system tumors

T2 - A Southwest Oncology Group study

AU - Taylor, Sarah A.

AU - Giroux, Dorothy J.

AU - Jaeckle, Kurt A.

AU - Panella, Timothy J.

AU - Dakhil, Shaker R.

AU - Schold, S. Clifford

N1 - Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA38926, CA32102, CA12644, CA58861, CA22433, CA46136, CA04920, CA58686, CA20319, CA46282, CA35431, CD35176, CA45560 and CA52654.

PY - 1998

Y1 - 1998

N2 - Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.

AB - Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.

KW - Central nervous system tumors

KW - Didemnin B

UR - http://www.scopus.com/inward/record.url?scp=0032457858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032457858&partnerID=8YFLogxK

U2 - 10.1023/A:1006273214056

DO - 10.1023/A:1006273214056

M3 - Article

C2 - 10426666

AN - SCOPUS:0032457858

SN - 0167-6997

VL - 16

SP - 331

EP - 332

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this